MedCrypt Inc.

MedCrypt Inc. is a cybersecurity company focused on securing medical devices by ensuring compliance with FDA requirements, offering innovative solutions for manufacturers in the healthcare sector. Founded in 2016 and headquartered in Solana Beach, US, MedCrypt specializes in cybersecurity for medical devices. The company has completed a total of 6 deals and recently secured USD 11.

40 mn in a Series B funding round led by Dexcom Ventures, bringing their total amount raised to USD 11. 40 mn. CEO Mike Kijewski leads the company, which has not undergone any significant operational pivots or structural changes since its inception. MedCrypt specializes in providing cybersecurity solutions tailored for medical device manufacturers, focusing on compliance with FDA cybersecurity requirements.

Their core offerings include the Helm tool, which enhances Software Bill of Materials (SBOM) management and vulnerability tracking, and the Guardian platform that facilitates secure device provisioning and certificate management. These products are designed to identify and mitigate vulnerabilities in medical devices, ensuring data integrity and privacy while streamlining incident response. MedCrypt's solutions are utilized by a diverse client base, ranging from startups to established enterprises in the medical device sector, with a geographical reach that extends into North America, Europe, and other international markets where regulatory compliance for medical devices is critical. MedCrypt generates revenue through a combination of service-oriented contracts and product licensing agreements with its clients in the medical device industry.

Their business transactions typically involve B2B engagements, where medical device manufacturers subscribe to their cybersecurity solutions to ensure compliance and enhance security measures for their products. The company's flagship products, such as Helm and Guardian, are offered in various pricing structures that correspond to the scale and specific needs of their clients. By providing continuous software security tools and consulting services, MedCrypt enables clients to expedite the regulatory approval process, thereby creating a stable revenue stream from ongoing support and compliance services. MedCrypt plans to leverage the recent funding from its Series B round to enhance product development, particularly focusing on new features within the Helm and Guardian platforms.

They are also targeting expansion into Europe and Asia-Pacific markets by 2025, aiming to cater to the growing demand for compliant cybersecurity solutions in these regions. With their recent funding, the company intends to solidify its market presence and enhance its product offerings, while navigating the exit of previous investors including Friedman Bioventures and Nex Cubed.